Jeffrey Jones
Chief Medical Officer CULLINAN THERAPEUTICS, INC.
Dr. Jeffrey Jones has over 20 years of clinical development experience in academia and industry, with skills ranging from clinical trials, drug development, medical education, and healthcare management. Prior to joining Cullinan, Dr. Jones held roles of increasing responsibility at Celgene and Bristol Myers Squibb, last serving as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases at Bristol Myers Squibb, where he led the development and life cycle management strategy for Reblozyl®. Before joining industry in 2017, Dr. Jones was Associate Professor of Internal Medicine in the Division of Hematology at The Ohio State University where he was an active clinical investigator in the lymphoid malignancies program.
Seminars
- How to improve preclinical models to better predict activity, clinical safety and de-risk translation into the clinic?
- How are next-generation preclinical platforms (e.g. organoids, humanised models, ex vivo systems) enabling evaluation of conditional activation and masking strategies?
- How can translational biomarker strategies, including antigen density thresholds and T-cell fitness profiling, improve patient stratification and clinical signal prediction?
- What will regulators most want to see before they are comfortable with first-in-human studies in these settings?
- Summarising emerging clinical data evaluating the safety, tolerability, and preliminary clinical activity of the CD19 x CD3 TCE CLN-978 across autoimmune patient populations
- Characterising the depth, durability, and tissue-level impact of B-cell depletion achieved through enhanced target engagement and extended half-life design
- Describing how emerging clinical and biomarker observations for CLN-978 can be utilised to rapidly advance the development of T cell engagers in autoimmune disease indications
